The reasons why teenagers and young adults (TYA) with cancer do, or do not, participate in clinical trials is not wholly understood. We explored the perceptions and experiences of young people with bone cancer, and health professionals involved in their care, with regard to participation in two clinical trials. We conducted semi-structured interviews using narrative inquiry with 21 young people aged 15-24 years and 18 health professionals. New understandings emerged about perceptions of, and factors that influence participation in, clinical trials. These include perceptions about the importance and design of the clinical trial, communicating with young people in an age-specific manner, using language young people are comfortable with, support from family, peers and specialists in teenage and young adult cancer care. We conclude that addressing these factors may increase acceptability of clinical trials and the trial design for TYA with cancer and ultimately improve their participation. Qualitative research has an important role in making explicit the perceptions and practices that ensure trials are patient-centred, appropriate and communicated effectively to TYA. Translating knowledge gained into routine practice, will go some way in ensuring that the disparities affecting this population are more fully understood.
INTRODUCTION
Recruitment to cancer clinical trials is recognised as an indicator of quality care and considered good practice. Clinical trials allow rigorous testing of new treatments with the possibility to impact on improvements in sur-vival for successive generations of cancer patients. Children's cancer care, where 5-year survival rates have improved from around 40% in the 1970s to almost 80% for those diagnosed today (Smith et al. 2010) , is a notable trial success story largely ascribed to high levels of participation in clinical trials. In England, inclusion of cancer patients in a clinical trial is advocated by health care policy (Department of Health 2007) and is underpinned by policy specific to children and young people (National Institute for Health and Clinical Excellence 2005) . A number of countries, including the United Kingdom (UK), have reported under-representation of teenagers and young adults (TYA) in cancer clinical trials, when compared to children or older adults. Some researchers have suggested this is associated with lesser survival gains for TYA (Bleyer 2005; Ferrari & Bleyer 2007) .
The perceived benefit of a clinical trial has been found to positively influence the decision of 12-to 22-year olds and their parents to participate (Read et al. 2009) , and the perceived burden of adolescents being asked to participate in a trial soon after a cancer diagnosis has also been reported (Broome et al. 2001) . Life stage transition across adolescence and young adulthood (Erikson 1995; Havighurst 1972) accompanied by care being delivered across children's and adult's health care settings (Bleyer 2007) are also reported as factors affecting trial participation in TYA. Quantitative research investigating the role of health professionals in TYA cancer trial participation has previously highlighted the role of organisational factors, for example increased participation in care settings where children's cancer trial protocols are offered compared to care settings where they are not (Parsons et al. 2011; Shochat et al. 2001) ; and the administrative burden of treating a patient on a clinical trial (Benjamin et al. 2000) . The clinical trial participation of TYA was also found to be negatively influenced by clinicians preference for treatment protocol over the clinical trial (Benjamin et al. 2000; Shaw & Ritchey 2007) .
Interest in TYA with cancer regarding clinical trial participation has recently gained momentum. Barakat et al. (2014) set out to understand decision-making patterns of 13 young people using semi-structured interviews with TYA, parents and health professionals; together with evaluating the Pediatric Research Participation Questionnaire (PRPQ). Barakat et al. (2014) reported that young people were not fully involved in decision-making, and suggested that stress, illness and immaturity impaired this. A process to enhance collaborative decision-making through structured diagnostic meetings was recommended. Following development of some questionnaire items, further exploration and validation, they suggest the PRPQ may help address barriers and benefits to trial participation.
Attitudes about clinical trial participation among 15-to 39-year-old survivors of lymphoma and leukaemia, and a healthy college sample, were identified using an Attitude Towards Cancer Trial Scales (Grigsby et al. 2014) . Fourteen were recruited who had cancer and were offered a clinical trial, of which eight participated. Grigsby et al. (2014) reported a positive attitude towards clinical trials; however, they also suggested that attitudes to TYA participation were not well understood and might impact on trial participation. They highlighted the need for exploratory work to further understand the complexities of personal, structural and contextual issues that affect cancer trial participation. This echoes recommendations of key authors about adult cancer clinical trials, where they emphasise the importance of qualitative interviews to understand experience (Cox 1998) and to explore decisionmaking (Cox & Avis 1996) . Understanding patient and professional perceptions of trial entry, along with trial protocol characteristics, have been identified as key to successful accrual (Cox & McGarry 2003; Maslin-Prothero 2006) .
Although there is growing interest in initiatives to increase enrolment of TYA into clinical studies (Weiss et al. 2015) , a continuing gap in our understanding of the perceptions and experiences of TYA participating in cancer clinical trials, may continue to hinder progress. We therefore sought to make a further contribution to the emerging evidence by seeking to expand our understanding of the perceptions and experiences of both TYAs and health professionals. To do this, we focused on two clinical trials for bone cancer: EURAMOS-1 (E-1) and . Bone cancer has a peak incidence in this age group, and unlike other cancer types has had less improvement in survival (Bleyer et al. 2006) . The 5-year survival rate is 50-60% (Whelan et al. 2012) , emphasising the need for further developments in treatment. In recent years, multinational groups have established large, collaborative, research projects to focus on bone sarcomas by undertaking clinical trials across multiple countries, which is a necessity given the rarity of these cancers (Whelan et al. 2015) . These trials had 'appropriate' age eligibility criteria, including the 15-24 age range; however, despite the appropriate age eligibility criteria, deficits in accrual of young adults to these clinical trials had still been observed. This suggests factors other than permissive age eligibility are involved (Fern et al. 2014) .
Both of these trials were long and complex with a staged consent process; this involved consenting to register on the trial very soon after diagnosis and consenting to ran-domised treatment after 3-4 months of chemotherapy. During this initial treatment period, very intense, standard chemotherapy was administered. This usually required extensive periods of hospitalisation, and caused significant side effects with some young people developing complications requiring intensive care or dose limitation. Surgery, which was sometimes extensive and involved amputation of limbs, followed this first course of chemotherapy. Radiotherapy was an additional requirement for many patients with Ewing sarcoma. Consent to treatment randomisation occurred shortly after surgery and pathological staging of the disease. Randomised treatment varied in intensity and duration for example, it could involve a further 18 months of treatment or high-dose chemotherapy (a simplified flow diagram of the stages of the trials is shown in Fig. 1 ).
The primary aim of this study was to explore the perception of teenagers, young adults and professionals in participating in bone cancer clinical trials using narrative interviews. To gain a comprehensive, in-depth understanding we gathered data from all stakeholders involved: potential trial participants, recruiting professionals and those who care for young people treated as part of the two clinical trials described. We hoped to gain a deeper understanding of the issues, experiences and perspectives of the stakeholders; identify factors important in trial design; understand the processes and contexts of recruitment; and ultimately contribute to strategies to increase enrolment to clinical studies for TYA.
METHODS

Design
A philosophy of interpretive interactionism that supports the study of meaning, which is grounded in the lives of individuals, was adopted for this study (Schwandt 2000) . We conducted interpretive qualitative interviews using narrative methods with all those involved in these two clinical trials. This was to explain and explore the 'whats' and 'hows' of personal stories to reveal how the meaning of trial participation is constructed over time (Sparkes 2005) . Focussing on both teenage and young adults, and health professionals, allowed for data to be triangulated, attempting to obtain a much deeper and broader understanding of the complexities of recruiting to and participating in these bone cancer clinical trials (Denzin 1978; Flick 1998) .
Narrative was used as a method to re-present experience (expressing and reconstituting it) (Squire 2008) . Reissman (2008) suggests narrative encompasses extended accounts of lives in contexts that develop over the course of single interviews or therapeutic conversations. In this study, narrative allowed the young people and health professionals to have a voice and facilitated the telling of the experience of participating in a clinical trial, the span of which extended over time.
Sample and setting
We recruited participants with primary bone cancer aged 15-24 years at diagnosis from a single, principal TYA treatment centre in the UK. The age range is defined as TYA according to the epidemiological age criteria used in England (National Institute for Health and Clinical Excellence 2005, p. 13). The setting was a well-developed bone and soft tissue sarcoma centre.
After discussion with the clinical team, we invited all TYA within this age range at diagnosis, and eligible to participate in E1 and EE99 between January 2009 and September 2011, to participate in this study. No TYA were excluded if they fitted these criteria. Twenty-one of 34 eligible young people agreed to participate. The TYAs were between 6 and 32 months from diagnosis at the time of interview, the age range was 15-25 years, with a median of 20 years; and 14 were men. Seven of the young people had Ewing's sarcoma, and were invited to participate in the EE-99 trial; the remaining 14 had osteosarcoma and were invited to participate in the E-1 trial. Nineteen registered on the trials, of those, 12 were eligible for randomised treatment, of which six consented. Only one TYA was eligible to consent to randomised treatment for the EE-99 trial, which they chose not to do.
We purposefully sampled professionals involved in the recruitment and care of TYA eligible for these trials. The care of TYAs in this principal treatment centre is undertaken across children's and adult oncology services and health professionals were sampled to reflect this service configuration. Professional participants included those directly involved in recruiting TYA into the clinical trials and supporting them during decisionmaking about clinical trial participation [including medical oncologists, registrars, clinical nurse specialists (CNS) and research nurses]; and those involved in the care of the TYAs when they were receiving treatment in the clinical trial (including chemotherapy nurses, ambulatory care and oncology ward managers, pharmacists and orthopaedic surgeons). Eighteen, of a total 29, health professionals invited agreed to participate. Nine professionals were directly involved in recruitment to the two bone cancer trials and nine professional were involved in the care of the TYAs receiving treatment in the trials. 
Ethics and consent
We obtained approval from a National Health Service research ethics committee (study reference: 11/LO/ 0523). It is worth noting that in England at 16, a young person is presumed to have capacity to consent to their own treatment (NHS Choices 2014). We therefore sent letters inviting young people, or their parent if less than 16 years, to directly contact the research team if they wished to opt-out and not receive further information. Young people were sent further information about the study and were later contacted by telephone. We emailed invitations to professionals, followed by a telephone call. For those potential participants wanting to participate in our research, we obtained written, informed consent, and assent and parental consent from those less than 16 years old. We assured all participants of anonymity, and that participation would remain confidential and that they could withdraw from the study at any time.
Methods of data collection
We used semi-structured narrative interviews to capture the perceptions and experience of all participants. AB conducted interviews using a collaborative, co-participatory process (Fontana & Frey 2000) ; providing an opportunity for participants to speak freely of their experience. An experienced TYA qualitative health researcher SP, supported AB in conducting the interviews. We initially asked the young person to tell their story from when they first heard about the clinical trial, after diagnosis, and then used the questions in a narrative structured interview style to focus on the chronology of events.
We identified open questions and probes from the literature (V. Lavender, E. Watson, R. Phillips and M. Boulton, unpublished data). We used reflective probes to paraphrase, encourage depth and demonstrate active listening to facilitate participants to tell their story (Wengraf 2001) . Some examples of probes included 'Can you tell me more about that?' and 'How did that make you feel?' (see Tables 1 and 2 ). Prior to data collection we refined the interview schedule with two young people with cancer from the research reference group. Interviews lasted on average 50 min. With permission, we digitally recorded and transcribed interviews. Parents, other family members, or friends were present during seven of the young peoples' interviews. Parents actively took part and answered questions in three interviews.
Data analysis
We analysed transcripts using an interpretative approach similar to that described by (Charmaz 2000) . This included memoing the transcripts, coding and constantly comparing codes to identify categories and themes. We continued this analysis until we had developed an emergent theoretical framework (Charmaz 2000) . We analysed data from TYA and health professional interviews separately. SP and AB read and coded all the transcripts. FG and VL coded a sample of transcripts to validate the coding process. To manage such large volumes of data, we began the process of developing an analytical framework following the first interview and through a process of ongoing review and assimilation developed a framework from the additional transcripts and their categories and themes. After the analytical frameworks were developed, SP and VL returned to the coded transcripts of all the interviews ensuring that nothing had been missed, adding another layer of rigour and review to the process. SP and VL then integrated themes and subcategories of the two analytical frameworks into an integrated analytical framework from both health professional and young person data. This allowed us to follow a thread and actively seek out similarities and differences within, and between, the two data sets (Moran-Ellis et al. 2006) . SP and VL used the integrated analytical framework to synthesise key findings of TYA participation in the bone cancer clinical trials.
RESULTS
We identified the following influencing factors across both data sets: perceptions and understanding of clinical trials, communication and information, support and coping, and the context of clinical trials and the culture of TYA specialist care. The influence of these factors on weighing up the benefits and burdens of clinical trial participation were most evident at critical time points of the young person's treatment experience. Participants' narratives highlighted the criticality of registration and randomisation, and to some degree the young people reflected on their experience over time. Time and the timing of events seemed significant to all those who participated in the study. We present a balance of interweaved quotes from young people and health professionals and a diagrammatic representation of the findings concludes our paper.
Influencing factors
Perception of clinical trials
Some TYA had learnt about clinical trials in science lessons at school; however, for most their knowledge was related either to information given by health professionals or their personal cancer experience. Some perceived clinical trials as synonymous with chemotherapy; others regarded it as an alternative treatment option. One participant suggested that, 'It's just another way of helping, find different ways to actually cure it faster and get people healthier quicker. So I think when I hear it, it's like another help, like a helpful organisation ' [TYA8: p16] . Some young people who had registered on the clinical trial, did not perceive receiving standard treatment following registration as a clinical trial and instead thought of the clinical trial as being something that happened at, or after, randomisation when trial treatment arms differed: I didn't really think about it. . . Like it [being on a trial] only would have made a difference if I'd got to randomisation and they said, "You're on the one that takes a month longer." I would, you know, it would just be, "no way". [TYA11: p18] Clinical trials were commonly described as being an experiment, with some TYAs describing 'feeling like a guinea pig'. This was not necessarily perceived negatively, but it was unnerving for some. Terminology used by health professionals may have influenced this perception. One professional discussed the importance of using the The possibility of improving the outcome of the disease for themselves, and the perceived benefit of helping others, outweighed the burden of participation for many of the young people:
If it's a little bit of information for the doctors to work out why it happens, then hopefully it will stop people having cancer, in the future or just create awareness, I don't know. . . I just hope there are benefits for everyone really. 
Communication and information
Communication and information, together with support and coping, were central to the experience of trial participation particularly at the times of registration and randomisation. Effective face-to-face communication and information provision was perceived as central for both TYAs and professionals. Face-to-face communication was discussed by the young people as being TYA-centred, reflecting the philosophy of TYA cancer care in the research setting. Professionals spoke about the value of working in a TYA care setting, where there was expertise in talking to young people. One TYA stated, 'They didn't talk to me like I was a child. They spoke to me as if it was my decision, it's my life, it's up to me' [TYA10: p19]. Written information was discussed as useful when the young people felt unwell, but they also discussed the fact that they might not feel up to reading. 'I might have looked at [the information] for two minutes and thought, Oh I can't read it now, they can do what they want to do ' [TYA9: p23] .
The language used in the communication with professionals was emphasised. Interpretation of the meaning of 'experiment', 'trial' and 'rare cancer' has already been highlighted. One young person found the use of the word 'cancer' difficult; and 'poor response' used at the time of randomisation provoked a strong, negative reaction in two participants. One participant stated, 'Oh for God's sake, I'm not a poor responder, I don't want to be a poor responder' [TYA21: p18]. Another was surprised at this choice of wording: Health professionals involved in recruitment of young people to the clinical trials used the term 'poor response' during their interviews as part of their everyday discourse about the clinical trial, and although they expressed anxiety about what the term meant in relation to tumour response, they did not express anxiety about using the term 'poor response' in relation to trial participation.
Enabling trust and building rapport over time, was identified by both TYAs and health professionals, as an important basis to facilitate good communication and ultimately trial decision-making. This was expressed by the young people, 'They made you feel really comfortable, they made you feel like at home sort of thing' [TYA3; p27], and by professionals, 'It's about developing the trust. . . between you and the patient. The more time and opportunities you have to do that, is good' [HP3: p6]. Some professionals were mindful of potential ethical implications of having a close rapport with a patient and then asking them to participate in research. One professional felt, 'If you have a good relationship with a patient and you've known them over a number of months, then they may sort of sub-consciously want to please you and want to do what they think you want them to do ' [HP7: p6] . Although the TYA in this study perceived health professionals who invited them to participate in a clinical trial had a vested interest in their participation, they did not perceive that their decision-making was influenced by trust or rapport with trial recruiters. Many participants did, however, emphasise the importance of the neutrality of the CNS with regard to these discussions.
All participants perceived dialogue between health professionals and young people was important. The CNS role was particularly highly valued by both TYA and other health professionals for their role in communication, information giving, support and coping. One professional stated, 'The CNS was the person that I feel is almost like an unbiased party that they can then ask any questions' [HP3: p6]. Young people discussed how the CNS was able to provide much valued neutrality. It enabled them to work through concerns face-to-face, to simplify the information imparted by professionals. It also allowed for discussion of the decision to participate in the clinical trial with a health professional who was not a 'clinical trial recruiter', and be an ongoing source of support, 'The CNS becomes like your friend, to be honest with you throughout all of this' [TYA20: p7].
Having the opportunity to ask questions was at the core of effective information giving and communication. Professionals spoke about the role of asking questions to be able to ascertain that young people had a full comprehension of the trial and its implications. For young people asking questions facilitated empowerment. 'For me the knowledge was what gave me power and gave me confidence in making decisions and if I didn't know something, I would ask, they encouraged my questioning ' [TYA7: p17] .
Support and coping
The support of family, peers and health professionals was fundamental to young people in being able to comprehend their diagnosis and treatment and cope with decisionmaking and the treatment experience. For a small number decision-making was family-centred. One young person described it as, 'The family having cancer, the family had osteosarcoma' [TYA8: p17]. Many professionals discussed family dynamics and the individuality of how families function. Family-centred decision-making was not attributed by professionals to the age of the young person, but more cognitive ability, emotional maturity, the family dynamic and the young person's role within the family. For most TYA, the family and others supported decisionmaking. One young person discussed support with regard to processing information:
Sometimes the words and the terminology that was used was a bit complex, so it was a bit lost in translation! But I think after my mum and dad had explained it to me, because they understood, then it helped me a lot to make more decisions. Sometimes there were differences in views about participation in the clinical trial between the TYA and parents. One professional recounted a difficult experience when one patient at randomisation had said they were doing it because of parental pressure. One young person in our research expressed regret about not participating because of a parent's influence: I said to my dad "I want to do it," my dad said "What if you do it and get more sick? You need to make things easier for yourself." And then, so yes that's why I said no to that trial. Young people, talked at length about the importance of hearing and sharing stories with peers who had similar experiences. There was a desire for a 'buddy' who was 'a few steps ahead' to inspire and give hope to a young person. One young person reflected, 'If somebody was to tell me that things would have got better and things get easier, I would have stayed on the trial. But nobody told me that' [TYA3: p21]. Health professionals completely understood the role of peer support, but for them it also raised concerns, 'If something goes poorly for somebody, they also hear that ' [HP13: p12] . Nevertheless, sharing their stories and experiences with others, and being able to support others, helped the participants know they were not alone and gave them a sense of feeling valued. One TYA described helping the mother of another young person with cancer, 'She was really worried because he [her son] was so sick and I explained to her that's how I was. She said that I was like a guardian angel' [TYA3: p21].
Context of care
All the TYA in this study emphasised the importance of being treated in a specialist care setting. Many were treated on a designated young persons' unit with peers, where there was also access to a wider psychosocial team. This, together with the specialist TYA skills and experience of the health professionals, was central to the experience of young people in this research.
One of the reasons that I'm here [being interviewed about participating in a bone cancer clinical trial] today, one of the reasons that I was able to get through the treatment with the disposition that I had. . ., was because I was surrounded by people of my own age that I could talk to, that I could help and they could help me. That the nurses and the doctors knew how to talk to me. [TYA7: p19] Professionals placed high value on working within an organisation that prioritised and supported clinical trials.
So, we are prepared to put in the legwork to, you know, to recruit patients. But part of that legwork is about the fact that it will add to your consultation time and you will need more than one consultation. . .. I think if you've got a big, well-resourced unit, then you are going to be able to put young people into trials. [HP 7: 11] Working within a team to provide timely support and information; feeling supported themselves by the team; and developing communication skills as a team were discussed in depth. Professional and organisational factors, such as team working and efficient infrastructure, were perceived by the health professionals as facilitating a culture that was conducive for the participation of TYA in bone cancer trials.
Critical time points
Registering on a clinical trial
Young people were typically registered on the trials within 2 weeks of receiving their cancer diagnosis, with discussions starting from the point of diagnosis. The timing of this was difficult for all young people. One young person described their thoughts about this, 'Oh this is another decision I've got to make, you know, I don't really want to -I'm not interested. . . . Why give someone this kind of decision when all this is going on already' [TYA1: p15]. Young people who had experienced a prolonged diagnostic journey felt a sense of urgency to start treatment. Pressure from the professionals to commence treatment was also experienced. One young person explained, 'I was quite rushed into it. But that was only because they wanted to start my treatment really straightaway ' [TYA13: p20] .
Ensuring that information was shared and understood, and consent was informed at this time, was perceived by some professional groups, such as research nurses, as difficult for both TYA and themselves professionally. One health care professional expressed, 'I think a lot of the time it's just too much information to take in. And I think the ones that turn it down, it is just too much' [HP18: p3]. Others, particularly medical professionals, directly responsible for obtaining consent, perceived registration as easier than randomisation. At registration they were explaining the opportunity to register on a trial initially with standard treatment and opt-out at a later date. Some TYA decided to register for the trial at this stage for this reason, 'We can make the decision to drop out. But we can't make a decision to drop in. So leave all doors available, all options open' [TYA7: p7]. For others, there was a strong sense of wanting to participate. Either to get better, '[I] just wanted to be well. I think even if I didn't understand, I would accept . . . I didn't want to have this pain again' [TYA5: p9], or to help others, 'If I can be part of a trial and make something, find a better way for people to be treated or an easier way to be treated, I don't mind being that guinea pig ' [TYA9: p8] .
Professionals also recognised altruism as a motivating factor, 'Generally the people are quite interested in taking part in research to help, to help other patients in the future really, if not for themselves ' [HP14: p4] . The timing of conversations was crucial; professionals recognised individual's distress at receiving a cancer diagnosis and during the registration process they consistently emphasised the importance of giving young people sufficient time and plenty of opportunities for communication, information and support.
Randomisation
Randomisation was expressed by most TYA and health professionals as the point when critical decisions were made. Consent to randomisation for both trials took place following surgery. Eligibility to the treatment arm of the clinical trials depended on treatment response. One professional explained, 'If the patient had a poor response that is going to be a harder conversation to have ' [HP3: p10] . This professional went on to explain the irony that although the good response conversation was the easiest to have, TYAs whose disease had responded well were often happier to stay with standard treatment and were less keen to be randomised. For many it was not an easy decision. One TYA described the anguish:
It was like, "you've had a poor histological response. And like what do you want to [do] ?" I couldn't make my mind up at the time, because in my head I had four months more left of treatment and I was looking at this longer one, it was like double the time. And more drugs as well. I was like, "oh my Some TYAs found the concept of randomisation and the concept of clinical equipoise difficult to comprehend. Being asked to make a (sometimes difficult) decision about receiving the treatment arm, when it was ultimately dependent upon a random computerised event took time for some young people to make sense of: 'I wanted to go on the trial, so the randomisation was a bit of a pointless thing to me, but then at the end of the day it gives everyone a chance to be on the trial' [TYA6: p10].
Others described how they would have felt disappointed if they had not received the experimental treatment arm, or would have preferred the professionals to make a decision for them. Despite the desire for control over choice of a treatment arm, both TYA and health professionals felt that the young people had better comprehension of what was involved, what treatment was like, and that decisionmaking and randomisation, if not easy, was more informed.
The decision-making process at randomisation involved weighing up the benefits and burdens of the treatment (see Fig. 2 ). Extended periods of hospitalisation were perceived as an unacceptable burden for many young people. Many needed to stay in hospital between chemotherapy treatments because of toxicities, which considerably limited the amount of time they were at home, 'If you can imagine that four out of the five weeks I was in hospital, and even when I wasn't in hospital, I felt I had a massive hangover from the worst night out you've probably ever had ' [TYA3: p16] .
Toxicity from the treatment was very powerfully described by many young people. A number were treated in intensive care units for treatment-related toxicity and a few had treatment toxicities that were dose-limiting or resulted in treatment cessation. The burdensome nature of treatment for bone sarcomas was fully understood and appreciated by the health professionals:
You know, they're probably some of the hardest chemotherapy regimens that I've ever worked with -that in itself without adding extra ten weeks or a couple of months to their sort of treatment time you know with some of them they are kind of, "Okay I've had enough". 
DISCUSSION
This is the first qualitative study that integrates data from TYAs with cancer and health professionals involved in their care, about recruitment to, and participation in clinical trials. Similar to other reports, our findings illustrate the multi-factorial nature of the experience of participating in clinical trials together with the ongoing decisionmaking process (Biedrzycki 2010) . We identified influencing factors and critical time points for young people eligible to participate in these two clinical trials (see Fig. 2 ).
The time of clinical trial registration soon after diagnosis when there was an imperative to start treatment urgently, was felt by many TYA and health professionals to be challenging; this is similar to other findings (Broome et al. 2001) . In addition, consultations about consenting to randomised treatment coincided with difficult discussions about treatment response, although there was a sense that having experienced treatment the young people were more informed.
We found that the prospect of prolonged treatment duration or increased treatment intensity on the experimental treatment arm often influenced the decision to participate. Adolescence and young adulthood compounded the sense of intensity and longevity of treatment for many TYA; they expressed urgency 'to get on with life' and referred to the poignancy of 'wasted time '. Mills et al. (2014) reported a study where they compared recruitment interviews by recruiters who had been trained and those who had not. Based on the effect training had on changing patients' perceptions about preferring a specific treatment, Mills et al. (2014) recommended training recruiters to explore patient preferences rather than accept them at face value. Our study did not specifically investigate the types of strategies used by recruiters to explore patient preferences, but it is an important area for both further research and practice.
Previous research with TYA highlights the importance of perceived benefits of participating in research to self (Broome et al. 2001) and others (Hendricks-Ferguson et al. 2013) , as central in decision-making. In this study benefit to self carries special meaning in the context of cancer clinical trials, where treatments may have significant adverse effects and survival is dependent on treatment effectiveness. Altruism was expressed as a reason to participate in both the bone cancer clinical trial and our research. The benefit for others often outweighed the burdens of trial participation for the young people.
Young people valued being placed at the centre of communication, which supported autonomous decisionmaking and reflected a highly evolved model of multidisciplinary TYA cancer care (Kelly et al. 2004) . Our findings contrast with findings reported by (Barakat et al. 2014) that TYA perceived low involvement in making decisions about clinical trial participation. The young peoples' accounts of language and communication used by professionals, suggests that both written and verbal communication are important influencers on their perception of clinical trials.
The value of the CNS as a support mechanism was evident and should be considered in strategies to enhance trial participation. The CNS was perceived by both young people and professionals as an essential party, being regarded as a 'neutral friend'; trust, support and rapport developed over time with other staff including key medical staff was also highly valued. These relational aspects of care could, however, have the potential to generate conflicts of interest when obtaining clinical trial consent. It is essential for health professionals to work within ethical frameworks and develop high levels of awareness and reflexivity within themselves and across teams (Finlay & Gough 2003) .
Our findings also illustrate the importance of support from, and support for, peers participating in the same clinical trial. Peer support is an aspect of care that is central to specialist TYA cancer care philosophy (Tai et al. 2014) .
Reflections on the study: strengths and limitations
Using a narrative approach facilitated the young people to reflect on their experience over time. The stories shared highlighted that the young people perceived the clinical trial as their treatment, rather than part of their treatment. Some young people expressed regret about not choosing to enter the randomised phase of the trial. The psychological effects of decision-making in terms of regret and guilt have been found in other studies (Stevens & Ahmedzai 2004; Biedrzycki 2010) . For others, participating in the clinical trial and/or having chemotherapy treatment marked a poignant period in their life story and participating in our research provided an opportunity for reflection. Some young people were still in one of the two clinical trials, some were 2 years after treatment. Of these a few were struggling to cope with life after cancer treatment. Two TYA had relapsed and one was receiving palliative treatment. These different time periods from data collection to when the TYA participated in the trials is a limitation of this research. Prospective longitudinal research, such as that by Stevens and Ahmedzai (2004) , would allow further exploration of experience over time.
Parents were present in some interviews. Although not actively encouraged, this could be seen as a reflection of the model of TYA cancer care, communicating with TYA within the context of the whole family, and the reality for professionals in clinical trial recruitment. The researcher who conducted the interviews, similar to the health professionals recruited to this research, kept the young person at the centre and prioritised their autonomy. However, there was flexibility in recognition of individual needs and dynamics and occasionally the parent took a participatory role in the conversationalstyle interview.
Using a narrative approach ensured participants of this study had an equal voice. Our findings reinforce the importance of hearing the perspective of both the young people and the health professionals who managed their care. Triangulating the data by integrating data sets from young people and health professional's added rigour to our study design, in addition to credibility, dependability and depth of the findings. The analysis was conducted by four members of the research team, none of whom had involvement with the clinical team, which added further dependability and trustworthiness to our findings. Recruiting participants from one hospital, together with using an opt-out recruitment process to promote autonomous decision-making and minimise potential gate-keeping (LeBlanc et al. 2013) , might have aided recruitment to our research. Future studies might, therefore, choose to consider the benefits of an opt-out approach to recruitment. et al. (2014) suggest an increase in TYA participation between 2005 and 2010 can be attributed to five key criteria, the five A's: Availability, Accessibility, Awareness, Appropriateness and Acceptability. They describe barriers and facilitators including: awareness of trials by both patients and health professionals; availability of open studies that TYA are eligible for; accessibility of the trial; appropriate trial design with age eligibly criteria that is permissive of inclusion of young people; and the acceptability of trial design for both patients and health professionals. Our study reinforces key messages in this publication and strengthens the call for the involvement of young people, and indeed professionals, in trial design at the outset. The National Institute for Health Research (National Institute for Health Research 2015) suggest that one method to do this is to involve patients as members of the research study group. However, there is concern that patient and public engagement in research, for example attending research advisory board meetings to discuss acceptability of the design of research studies, can be tokenistic and better methods of engaging stakeholders in research are still needed (Domecq et al. 2014) . One method is by incorporating findings of qualitative research that recruits key stakeholders in the design and implementation of clinical trials. Although the use of qualitative research to engage stakeholders early in trial design is recommended by Barakat et al. (2014) and Woolfall et al. (2014) , Gamble et al. (2014) argue that more research is needed to describe its contribution to research. Our study demonstrates use of qualitative research, either prior to or alongside clinical trials, is central to developing a deeper understanding of the acceptability of a clinical trial based on stakeholder perspectives and experiences.
Implications for research
Fern
Implications for practice
The setting for our study was a well-established specialist TYA cancer centre, and thus had a consistent and speciality-focussed multidisciplinary team delivering treatment, trials, and both psychosocial and developmental aspects of TYA cancer care. It is important to acknowledge the different contexts in which young people with cancer are cared for. Although TYA with bone cancer would usually be treated in similar contexts in the UK, young people with other tumour types might be cared for in non-specialist settings. Ongoing review by clinical teams of trial participation and sharing of the experience of the specific challenges of a trial to other centres should become routine. Similar to other researchers, such as O'Cathain et al.
(2013) and How et al. (2015) , we also agree that it is important for qualitative research to impact on, and be disseminated in, practice in the context of designing and implementing clinical trials.
For our study to have its greatest impact on specialist TYA cancer care, we suggest a number of essential elements are required to reduce the known barriers and increase the facilitators described here to participating in a clinical trial. For example, sharing information with TYA about a trial should be individualised; young people should be supported through the decision-making process, making time and allowances for family involvement and support from peers; and young people should be guided about what it is important for them to ask about the trial.
The provision of neutral support to patients by CNS is essential within a team of health professionals that offer clinical trials. This role should perhaps also be included in trial communication and information such as initiation visits to ensure their familiarity with individual trials. In addition, since caring relationships are primarily built on trust, professional education and support strategies, that might be additional to good clinical practice training currently provided in the UK, are needed to ensure effective communication with patients who are invited to participate in a clinical trial. This could include the development of 'scripts' or 'prompts' that professionals might use in discussion with future potential participants.
CONCLUDING THOUGHTS
This qualitative study provides a deeper understanding of the perceptions and experiences of key stakeholders in TYA cancer trials. It has identified factors important in trial design, and as such contributes to an increasing awareness of the importance of the processes and contexts of recruitment to both clinical trials and treatment delivery. Our study also emphasises a role for qualitative research in clinical trials, from early stages of trial design to ongoing evaluation and review, to ensure trials are patient-centred. It is essential that findings such as these are translated into practice, which alongside further research, will ultimately contribute to strategies that increase enrolment and retention to clinical studies for TYA. This would support our primary aim to improve young peoples' outcomes from cancer, which we know are influenced by participation in clinical trials.
